Citation Impact
Citing Papers
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines
2011
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
2011 StandoutNobel
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
2010 StandoutNobel
Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer
2005
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
2020 StandoutNobel
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer
2007
Engineering precision nanoparticles for drug delivery
2020 Standout
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Dendritic cells as therapeutic vaccines against cancer
2005
Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro
2007
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Immunosuppressive networks in the tumour environment and their therapeutic relevance
2005 Standout
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Features of the dendritic cell lineage
2010 StandoutNobel
Natural mechanisms protecting against cancer
2003
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome
2007 StandoutNobel
Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited
2009
Tumour immunity: effector response to tumour and role of the microenvironment
2008
IL‐15‐induced human DC efficiently prime melanoma‐specific naive CD8+ T cells to differentiate into CTL
2007
The Human T Cell Response to Melanoma Antigens
2006
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Coordinated regulation of myeloid cells by tumours
2012 Standout
Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells
2005
Cancer immunotherapy via dendritic cells
2012 Standout
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Immune checkpoint inhibitors in melanoma
2021
Thermal ablation of tumours: biological mechanisms and advances in therapy
2014 Standout
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Imiquimod Enhances the Systemic Immunity Attained by Local Cryosurgery Destruction of Melanoma Lesions
2007
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
2016
Tumor‐reactive CD8+ T‐cell responses after vaccination with NY‐ESO‐1 peptide, CpG 7909 and Montanide® ISA‐51: association with survival
2009
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient
2011
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
2006
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
2017 Standout
Dendritic Cells In Vivo: A Key Target for a New Vaccine Science
2008 StandoutNobel
VEGF-targeted therapy: mechanisms of anti-tumour activity
2008 Standout
Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
2016
Prospects for exosomes in immunotherapy of cancer
2006
Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell Immunity
2006
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
2017
Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity
2010
Regulatory T cells in tumor immunity
2010 StandoutNobel
Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells
2010 Standout
Cancer/testis antigens, gametogenesis and cancer
2005 Standout
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
2018
The secret ally: immunostimulation by anticancer drugs
2012
Cancer as an evolutionary and ecological process
2006 Standout
Cancer vaccines and carbohydrate epitopes
2011
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
2017
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Manipulating dendritic cell biology for the active immunotherapy of cancer
2004
Immune‐checkpoint molecules on regulatory T‐cells as a potential therapeutic target in head and neck squamous cell cancers
2020
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
2008 StandoutNobel
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
A subset of dendritic cells induces CD4+ T cells to produce IFN-γ by an IL-12–independent but CD70-dependent mechanism in vivo
2007 StandoutNobel
Translational nanoparticle engineering for cancer vaccines
2017
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery
2004
Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage
2006
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
2016
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Metastatic Prostate Cancer
2018
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
2006
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
2008 StandoutNobel
Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells
2004
Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses
2006 StandoutNobel
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Works of Phillip Parente being referenced
Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients
2006
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
2016
Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
2015
Immunodominant CD4 + responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
2004
Early recognition of ipilimumab‐related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management
2015
Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination.
2005
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy.
2015
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.
2004
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA
2017
Rational approaches to human cancer immunotherapy
2003